Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of Sunitinib Malate Depot Formulation (GB-102) Compared to Aflibercept in Subjects With Neovascular (Wet) Age-related Macular Degeneration (ALTISSIMO Study)

NCT03953079 is registered in ClinicalTrials.gov with Graybug Vision as lead sponsor.

NCT NCT03953079
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03953079 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of Sunitinib Malate Depot Formulation (GB-102) Compared to Aflibercept in Subjects With Neovascular (Wet) Age-related Macular Degeneration (ALTISSIMO Study)
Lead sponsor
Graybug Vision
Phase
Phase 2
Overall status
Completed
Start date
September 26, 2019
Completion date
June 3, 2021
Enrollment
56 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration